Jupiter Asset Management Ltd. Invests $5.74 Million in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Key Points

• Jupiter Asset Management Ltd. invested $5.74 million in Lantheus Holdings, Inc., acquiring approximately 58,829 shares during the first quarter.
• Institutional investors own a significant 99.06% of Lantheus's stock, with several hedge funds increasing their stakes in the company.
• Lantheus reported a loss of $0.11 per share against analyst expectations in their latest earnings report, with a revenue of $372.76 million, slightly lower than estimates.

Jupiter Asset Management Ltd. acquired a new position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) during the first quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 58,829 shares of the medical equipment provider's stock, valued at approximately $5,742,000. Jupiter Asset Management Ltd. owned 0.09% of Lantheus at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in LNTH. Mirae Asset Global Investments Co. Ltd. grew its stake in Lantheus by 3.4% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 12,084 shares of the medical equipment provider's stock valued at $1,162,000 after acquiring an additional 400 shares during the period. State of Alaska Department of Revenue grew its stake in Lantheus by 2.7% in the 1st quarter. State of Alaska Department of Revenue now owns 8,142 shares of the medical equipment provider's stock valued at $794,000 after acquiring an additional 215 shares during the period. GAMMA Investing LLC grew its stake in Lantheus by 12,517.1% in the 1st quarter. GAMMA Investing LLC now owns 128,442 shares of the medical equipment provider's stock valued at $12,536,000 after acquiring an additional 127,424 shares during the period. Pictet Asset Management Holding SA grew its stake in Lantheus by 12.1% in the 4th quarter. Pictet Asset Management Holding SA now owns 10,294 shares of the medical equipment provider's stock valued at $921,000 after acquiring an additional 1,113 shares during the period. Finally, Cerity Partners LLC grew its stake in Lantheus by 12.7% in the 1st quarter. Cerity Partners LLC now owns 11,709 shares of the medical equipment provider's stock valued at $1,143,000 after acquiring an additional 1,323 shares during the period. Institutional investors and hedge funds own 99.06% of the company's stock.

Insider Transactions at Lantheus

In other Lantheus news, Director Mary Anne Heino sold 26,066 shares of Lantheus stock in a transaction on Monday, June 2nd. The shares were sold at an average price of $76.83, for a total transaction of $2,002,650.78. Following the sale, the director owned 318,650 shares of the company's stock, valued at $24,481,879.50. The trade was a 7.56% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 2.00% of the stock is currently owned by company insiders.

Lantheus Trading Down 0.9%

Shares of LNTH opened at $70.57 on Monday. Lantheus Holdings, Inc. has a 52-week low of $69.12 and a 52-week high of $118.21. The company has a quick ratio of 5.46, a current ratio of 5.74 and a debt-to-equity ratio of 0.49. The firm's fifty day moving average is $77.65 and its two-hundred day moving average is $87.91. The stock has a market cap of $4.88 billion, a PE ratio of 20.05 and a beta of 0.14.

Lantheus (NASDAQ:LNTH - Get Free Report) last announced its earnings results on Wednesday, May 7th. The medical equipment provider reported $1.53 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.64 by ($0.11). Lantheus had a return on equity of 36.99% and a net margin of 16.55%. The business had revenue of $372.76 million for the quarter, compared to analyst estimates of $377.37 million. During the same period last year, the firm earned $1.69 EPS. The company's revenue for the quarter was up .8% compared to the same quarter last year. Research analysts forecast that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

LNTH has been the topic of a number of research analyst reports. Truist Financial dropped their price target on shares of Lantheus from $127.00 to $117.00 and set a "buy" rating on the stock in a research note on Thursday, May 8th. Wall Street Zen raised shares of Lantheus from a "hold" rating to a "buy" rating in a research note on Thursday, May 8th. B. Riley dropped their price target on shares of Lantheus from $122.00 to $109.00 and set a "buy" rating on the stock in a research note on Monday, June 23rd. Finally, William Blair reissued a "market perform" rating on shares of Lantheus in a research note on Wednesday, July 16th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company's stock. Based on data from MarketBeat.com, Lantheus has a consensus rating of "Moderate Buy" and an average price target of $131.20.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.